X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
VGL101 is a fully human monoclonal antibody targeting human TREM2, which is responsible for maintaining microglial cell function. TREM2 deficiency is believed to be a driver of certain neurodegenerative diseases.
Lead Product(s): VGL101
Therapeutic Area: Rare Diseases and Disorders Product Name: VGL101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
VG-3927 is designed to act as a molecular glue that potentiates the TREM2 signaling response to natural damage ligands and brain-penetrant small molecule.
Lead Product(s): VG-3927
Therapeutic Area: Neurology Product Name: VG-3927
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2023
Details:
VGL101 is a fully human monoclonal antibody targeting human TREM2, which is responsible for maintaining microglial cell function. TREM2 deficiency is believed to be a driver of certain neurodegenerative diseases.
Lead Product(s): VGL101
Therapeutic Area: Genetic Disease Product Name: VGL101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2023
Details:
Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Lead Product(s): VGL101
Therapeutic Area: Neurology Product Name: VGL101
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $112.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 03, 2022
Details:
Its lead candidate, VGL101, is a fully human monoclonal antibody (mAb) that is initially being developed for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).
Lead Product(s): VGL101
Therapeutic Area: Neurology Product Name: VGL101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 19, 2021
Details:
VGL101, a fully human monoclonal antibody agonist targeting triggering receptor expressed on myeloid cells 2 treatment of patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia.
Lead Product(s): VGL101
Therapeutic Area: Neurology Product Name: VGL101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 15, 2021
Details:
Series B financing further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration which include both a fully human monoclonal antibody, VGL101, and small molecule agonists of triggering receptor on myeloid cells 2 (TREM2).
Lead Product(s): VGL101
Therapeutic Area: Neurology Product Name: VGL101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vida Ventures
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing August 18, 2021
Details:
Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline.
Lead Product(s): VGL101
Therapeutic Area: Neurology Product Name: VGL101
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Atlas Venture
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing December 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
